1. Home
  2. KODK vs REPL Comparison

KODK vs REPL Comparison

Compare KODK & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastman Kodak Company Common New

KODK

Eastman Kodak Company Common New

HOLD

Current Price

$8.86

Market Cap

705.6M

ML Signal

HOLD

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

HOLD

Current Price

$10.59

Market Cap

721.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KODK
REPL
Founded
1880
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
705.6M
721.7M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
KODK
REPL
Price
$8.86
$10.59
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$12.00
AVG Volume (30 Days)
2.0M
2.0M
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,045,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.93
$2.68
52 Week High
$9.31
$14.80

Technical Indicators

Market Signals
Indicator
KODK
REPL
Relative Strength Index (RSI) 70.42 71.76
Support Level $7.50 $9.35
Resistance Level $8.67 $11.26
Average True Range (ATR) 0.43 0.62
MACD 0.11 0.04
Stochastic Oscillator 82.12 75.54

Price Performance

Historical Comparison
KODK
REPL

About KODK Eastman Kodak Company Common New

Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Share on Social Networks: